1
|
Barnhart AS, Anthony AL, Conaway KR, Sibbitt BG, Delaney E, Haluschak J, Kathula S, Chen A. Safety and efficacy of Vitamin C, Vitamin E, and selenium supplementation in the oncology setting: A systematic review. J Oncol Pharm Pract 2023:10781552231182362. [PMID: 37321210 DOI: 10.1177/10781552231182362] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/17/2023]
Abstract
OBJECTIVE With rising rates of complementary and alternative medicine (CAM) use, the exploration of CAM integration into oncology treatments is becoming increasingly prevalent. Antioxidants have been proposed as potentially beneficial to prevent or treat cancer. However, evidence summaries are limited, and the United States Preventive Services Task Force has recently recommended the use of Vitamin C and E supplementation for cancer prevention. Thus, the objective of this systematic review is to evaluate the existing literature on the safety and efficacy of antioxidant supplementation in oncology patients. METHODS A systematic review was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, using prespecified search terms in PubMed and CINAHL. Two reviewers independently reviewed titles, abstracts, and full-text articles, with a third reviewer resolving conflicts, before the included articles underwent data extraction and quality appraisal. RESULTS Twenty-four articles met the inclusion criteria. Of the included studies, nine evaluated selenium, eight evaluated Vitamin C, four evaluated Vitamin E, and three of these studies included a combination of two or more of these agents. The most frequently evaluated cancer types included colorectal cancer (n = 4), leukemias (n = 4), breast cancer (n = 3), and genitourinary cancers (n = 3). Most of the studies focused on the antioxidants' therapeutic efficacy (n = 15) or their use in protecting against chemotherapy- or radiation-induced side effects (n = 8), and one study evaluated the role of an antioxidant in protection against cancer. Findings were generally favorable among the studies, and adverse effects of supplementation were limited. Furthermore, the average score for all the included articles on the Mixed Methods Appraisal Tool was 4.2, indicating the high quality of the studies. CONCLUSIONS Antioxidant supplements may provide benefits in reducing incidence or severity of treatment-induced side effects with limited risk for adverse effects. Large, randomized controlled trials are needed to confirm these findings among various cancer diagnoses and stages. Healthcare providers should understand the safety and efficacy of these therapies to address questions that arise in caring for those with cancer.
Collapse
Affiliation(s)
- A S Barnhart
- School of Pharmacy, Cedarville University, Cedarville, OH, USA
| | - A L Anthony
- School of Pharmacy, Cedarville University, Cedarville, OH, USA
| | - K R Conaway
- School of Pharmacy, Cedarville University, Cedarville, OH, USA
| | - B G Sibbitt
- School of Pharmacy, Cedarville University, Cedarville, OH, USA
| | | | | | | | - Amh Chen
- School of Pharmacy, Cedarville University, Cedarville, OH, USA
| |
Collapse
|
2
|
Evrard YA, Eugeni M, Ahalt-Gottholm M, Bonomi C, Borgel S, Caffrey TC, Carter J, Chang TC, Chen L, Cooper K, Das B, Delaney E, Dougherty K, Duregon E, Ecker S, Geraghty J, Gibson M, Hicks L, Hull J, Veldt SI, Jiwani S, Karlovich CA, Loewenstein J, Mallow C, McGlynn C, Mills J, Miner T, Schneider J, Shearer T, Styers S, Uzelac S, Grandgenett P, Hollingsworth M, Hooper JE, Williams PM, Hollingshead M, Doroshow JH. Abstract 3120: Method development for generation of PDX models from rapid autopsy samples for the NCI patient-derived models repository. Cancer Res 2022. [DOI: 10.1158/1538-7445.am2022-3120] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
NCI’s Patient-Derived Models Repository (NCI PDMR; pdmr.cancer.gov) has developed a variety of patient-derived models across most solid tumor histologies. These models are early passage, genetically characterized and associated with limited patient treatment history. As part of this effort, the NCI PDMR worked with the University of Nebraska Medical Center Rapid Autopsy Program and Johns Hopkins University Legacy Gift Rapid Autopsy Program to develop and optimize methods for collection, processing, and shipping of autopsy tumor material to maintain viability during overnight transit for use in patient-derived model development. These methods have been successfully transferred to two other participating rapid autopsy programs. To date, 412 autopsy tumor samples from 76 consented patients have been received for model development; 348 shipped overnight in media for next day implantation into NSG host mice and 64 cryopreserved prior to shipping for a comparative assessment of take-rate versus fresh tumor samples. On average 3-8 tumor samples, primary and metastatic, were collected post-mortem from the truncal region of each patient. Histologies include Pancreatic adenocarcinoma (n=43), Cholangiocarcinoma (n=6), Prostate adenocarcinoma (n=6), and 21 others with 1-2 patients/histology. The overall age range of enrolled patients was 5-88yo. The post-mortem cold ischemic time for collections ranged from 1.5 to 20 hours with a median of 3h (avg. 3.75h; outlier >11h removed). Collection methods were optimized to reduce contamination and increase viability of tumor tissues for successful PDX model generation. Of 348 fresh tumor samples collected to date, 69 PDX models from 33 patients have been generated (range 1-6 models/patient) and an additional 55 samples are being monitored for growth in passage 0. The largest public single-patient PDX model sets are for melanoma (899932-113-R, n=6) and two pancreatic adenocarcinomas (521955-158-R, n=6, 217524-143-R, n=4). Important methods for reducing contaminants in autopsy tumor material include sterilization of the surface of the body prior to opening, use of sterile fields, using separate sterile instruments for each collection site, rinsing the surface of the resected tumor tissue, and use of antibiotics in the collection media. The now established SOPs are publicly available on the NCI PDMR website (pdmr.cancer.gov/sops). We recommend incorporating as many of these methods as possible within the limitations of your individual site. Of the 69 models developed to date, 48 are publicly available from the NCI PDMR while the rest are undergoing quality control process prior to public release. Models developed from autopsy material provide a research tool to investigate tumor evolution, differences between primary and metastatic lesions, and assessment of differences in therapeutic response based on differences in the tumor biology.
Citation Format: Yvonne A. Evrard, Michelle Eugeni, Michelle Ahalt-Gottholm, Carrie Bonomi, Suzanne Borgel, Thomas C. Caffrey, John Carter, Ting-Chia Chang, Li Chen, Kevin Cooper, Biswajit Das, Emily Delaney, Kelly Dougherty, Eleonora Duregon, Stephanie Ecker, Joe Geraghty, Marion Gibson, Lauren Hicks, Jenna Hull, Sharon Int Veldt, Shahanawaz Jiwani, Chris A. Karlovich, Jade Loewenstein, Candace Mallow, Chelsea McGlynn, Justine Mills, Tiffanie Miner, Jowaly Schneider, Tia Shearer, Savanna Styers, Shannon Uzelac, Paul Grandgenett, Michael Hollingsworth, Jody E. Hooper, P. Mickey Williams, Melinda Hollingshead, James H. Doroshow. Method development for generation of PDX models from rapid autopsy samples for the NCI patient-derived models repository [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 3120.
Collapse
Affiliation(s)
- Yvonne A. Evrard
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | | | | | - Carrie Bonomi
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Suzanne Borgel
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | | | - John Carter
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Ting-Chia Chang
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Li Chen
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Kevin Cooper
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Biswajit Das
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Emily Delaney
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Kelly Dougherty
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | | | - Stephanie Ecker
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Joe Geraghty
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Marion Gibson
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Lauren Hicks
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Jenna Hull
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Sharon Int Veldt
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | | | | | - Jade Loewenstein
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Candace Mallow
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Chelsea McGlynn
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Justine Mills
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Tiffanie Miner
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | | | - Tia Shearer
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Savanna Styers
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Shannon Uzelac
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | | | | | | | | | | | | |
Collapse
|
3
|
Chen L, Pauly R, Chang TC, Das B, Evrard YA, Karlovich CA, Vilimas T, Chapman A, Nair N, Romero L, Fong AL, Peach A, Jiwani S, Neishaboori N, Dutko L, Benauer K, Rivera G, Cantu E, Camalier C, Forbes T, Gottholm-Ahalt M, Carter J, Borgel S, McGlynn C, Mallow C, Delaney E, Miner T, Eugeni MA, Newton D, Hollingshead MG, Williams PM, Doroshow JH. Abstract 80: Genomic characterization of PDX models from rare cancer patients in the NCI Patient-Derived Models Repository. Cancer Res 2022. [DOI: 10.1158/1538-7445.am2022-80] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: The National Cancer Institute’s Patient-Derived Models Repository (NCI PDMR; https://pdmr.cancer.gov) has developed a large number of patient-derived xenograft (PDX) models from a diverse set of rare cancers. These models have been genomically characterized using whole-exome sequencing (WES) and RNAseq. The resource provides a unique opportunity to explore the genomic features of rare tumor models in NCI PDMR and to understand the oncogenic processes in pre-clinical models to identify biomarkers associated with therapeutic responses.
Methods: Genomic characterization was done in 4-6 PDX samples across multiple passages and lineages from each model. As the samples exhibited a high level of genomic stability within each model, consensus mutation and copy number variation (CNV), microsatellite instability (MSI), genomic loss of heterozygosity (LOH), homologous recombination deficiency score (scarHRD), and mutational signature data were generated from WES. Fusions were identified from RNASeq data using Star-Fusion and FusionInspector. Gene set enrichment analysis was conducted from the gene expression data obtained from RNAseq.
Results: 1) 233 PDX models have been developed and characterized from more than 45 different rare malignancies. Most frequent cancer types are different sarcomas (n=63), head & neck squamous cell carcinoma (n=61), and malignant fibrous histiocytoma (MFH) (n=11); 2) TP53 was the most frequently altered gene, mutated in 51% of models, followed by NOTCH1 (16%) and PIK3CA (11%). In terms of CNVs, ovarian epithelial cancer (OVT) showed relatively high chromosomal instability, while uterine endometrioid carcinoma (UEC) and synovial sarcoma (SYNS) had low instability; 3) MSI-H was observed in only 7 models. Esophageal adenocarcinoma (ESCA), OVT, and cervical squamous cell carcinoma (CESC) had high scarHRD and genomic LOH scores, while both scores were low in UEC and anal squamous cell carcinoma (ANSC). COSMIC v2 mutational signature 3 is significantly associated with a high scarHRD score (p-value < 0.01, Wilcoxon rank-sum test); 4) Characteristic fusions were observed in certain sarcoma models: SS18-SSX1 and ASPSCR1-TFE3 fusions were observed in SYNS and alveolar soft part sarcoma (ASPS) models respectively. EWSR1-FLI1 fusion was present in 2 out of 3 Ewing sarcoma (ES) models. 5) Gene set enrichment analysis from RNASeq data showed that epithelial-mesenchymal transition score could accurately distinguish carcinoma from sarcoma models, confirming the divergent gene expression programs.
Conclusion: Comprehensive genomic characterization of NCI PDMR models generated from rare cancers solves an unmet need in the community. It will serve as a valuable resource for translational researchers interested in pre-clinical drug development and discovery.
Citation Format: Li Chen, Rini Pauly, Ting-Chia Chang, Biswajit Das, Yvonne A. Evrard, Chris A. Karlovich, Tomas Vilimas, Alyssa Chapman, Nikitha Nair, Luis Romero, Anna Lee Fong, Amanda Peach, Shahanawaz Jiwani, Nastaran Neishaboori, Lindsay Dutko, Kelly Benauer, Gloryvee Rivera, Erin Cantu, Corinne Camalier, Thomas Forbes, Michelle Gottholm-Ahalt, John Carter, Suzanne Borgel, Chelsea McGlynn, Candace Mallow, Emily Delaney, Tiffanie Miner, Michelle A. Eugeni, Dianne Newton, Melinda G. Hollingshead, P. Mickey Williams, James H. Doroshow. Genomic characterization of PDX models from rare cancer patients in the NCI Patient-Derived Models Repository [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 80.
Collapse
Affiliation(s)
- Li Chen
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Rini Pauly
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Ting-Chia Chang
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Biswajit Das
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Yvonne A. Evrard
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | | | - Tomas Vilimas
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Alyssa Chapman
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Nikitha Nair
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Luis Romero
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Anna Lee Fong
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Amanda Peach
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | | | | | - Lindsay Dutko
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Kelly Benauer
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Gloryvee Rivera
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Erin Cantu
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Corinne Camalier
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Thomas Forbes
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | | | - John Carter
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Suzanne Borgel
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Chelsea McGlynn
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Candace Mallow
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Emily Delaney
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Tiffanie Miner
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | | | - Dianne Newton
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | | | | | | |
Collapse
|
4
|
Kim BY, Wang JR, Miller DE, Barmina O, Delaney E, Thompson A, Comeault AA, Peede D, D'Agostino ERR, Pelaez J, Aguilar JM, Haji D, Matsunaga T, Armstrong E, Zych M, Ogawa Y, Stamenković-Radak M, Jelić M, Veselinović MS, Tanasković M, Erić P, Gao JJ, Katoh TK, Toda MJ, Watabe H, Watada M, Davis JS, Moyle LC, Manoli G, Bertolini E, Košťál V, Hawley RS, Takahashi A, Jones CD, Price DK, Whiteman N, Kopp A, Matute DR, Petrov DA. Correction: Highly contiguous assemblies of 101 drosophilid genomes. eLife 2022; 11:e78579. [PMID: 35302486 PMCID: PMC8933002 DOI: 10.7554/elife.78579] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2022] [Accepted: 03/11/2022] [Indexed: 11/13/2022] Open
|
5
|
Kim BY, Wang JR, Miller DE, Barmina O, Delaney E, Thompson A, Comeault AA, Peede D, D'Agostino ERR, Pelaez J, Aguilar JM, Haji D, Matsunaga T, Armstrong EE, Zych M, Ogawa Y, Stamenković-Radak M, Jelić M, Veselinović MS, Tanasković M, Erić P, Gao JJ, Katoh TK, Toda MJ, Watabe H, Watada M, Davis JS, Moyle LC, Manoli G, Bertolini E, Košťál V, Hawley RS, Takahashi A, Jones CD, Price DK, Whiteman N, Kopp A, Matute DR, Petrov DA. Highly contiguous assemblies of 101 drosophilid genomes. eLife 2021; 10:e66405. [PMID: 34279216 PMCID: PMC8337076 DOI: 10.7554/elife.66405] [Citation(s) in RCA: 57] [Impact Index Per Article: 19.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2021] [Accepted: 07/16/2021] [Indexed: 12/13/2022] Open
Abstract
Over 100 years of studies in Drosophila melanogaster and related species in the genus Drosophila have facilitated key discoveries in genetics, genomics, and evolution. While high-quality genome assemblies exist for several species in this group, they only encompass a small fraction of the genus. Recent advances in long-read sequencing allow high-quality genome assemblies for tens or even hundreds of species to be efficiently generated. Here, we utilize Oxford Nanopore sequencing to build an open community resource of genome assemblies for 101 lines of 93 drosophilid species encompassing 14 species groups and 35 sub-groups. The genomes are highly contiguous and complete, with an average contig N50 of 10.5 Mb and greater than 97% BUSCO completeness in 97/101 assemblies. We show that Nanopore-based assemblies are highly accurate in coding regions, particularly with respect to coding insertions and deletions. These assemblies, along with a detailed laboratory protocol and assembly pipelines, are released as a public resource and will serve as a starting point for addressing broad questions of genetics, ecology, and evolution at the scale of hundreds of species.
Collapse
Affiliation(s)
- Bernard Y Kim
- Department of Biology, Stanford UniversityStanfordUnited States
| | - Jeremy R Wang
- Department of Genetics, University of North CarolinaChapel HillUnited States
| | - Danny E Miller
- Department of Pediatrics, Division of Genetic Medicine, University of Washington and Seattle Children’s HospitalSeattleUnited States
| | - Olga Barmina
- Department of Evolution and Ecology, University of California DavisDavisUnited States
| | - Emily Delaney
- Department of Evolution and Ecology, University of California DavisDavisUnited States
| | - Ammon Thompson
- Department of Evolution and Ecology, University of California DavisDavisUnited States
| | - Aaron A Comeault
- School of Natural Sciences, Bangor UniversityBangorUnited Kingdom
| | - David Peede
- Biology Department, University of North CarolinaChapel HillUnited States
| | | | - Julianne Pelaez
- Department of Integrative Biology, University of California, BerkeleyBerkeleyUnited States
| | - Jessica M Aguilar
- Department of Integrative Biology, University of California, BerkeleyBerkeleyUnited States
| | - Diler Haji
- Department of Integrative Biology, University of California, BerkeleyBerkeleyUnited States
| | - Teruyuki Matsunaga
- Department of Integrative Biology, University of California, BerkeleyBerkeleyUnited States
| | | | - Molly Zych
- Molecular and Cellular Biology Program, University of WashingtonSeattleUnited States
| | - Yoshitaka Ogawa
- Department of Biological Sciences, Tokyo Metropolitan UniversityHachiojiJapan
| | | | - Mihailo Jelić
- Faculty of Biology, University of BelgradeBelgradeSerbia
| | | | - Marija Tanasković
- University of Belgrade, Institute for Biological Research "Siniša Stanković", National Institute of Republic of SerbiaBelgradeSerbia
| | - Pavle Erić
- University of Belgrade, Institute for Biological Research "Siniša Stanković", National Institute of Republic of SerbiaBelgradeSerbia
| | - Jian-Jun Gao
- School of Ecology and Environmental Science, Yunnan UniversityKunmingChina
| | - Takehiro K Katoh
- School of Ecology and Environmental Science, Yunnan UniversityKunmingChina
| | | | - Hideaki Watabe
- Biological Laboratory, Sapporo College, Hokkaido University of EducationSapporoJapan
| | - Masayoshi Watada
- Graduate School of Science and Engineering, Ehime UniversityMatsuyamaJapan
| | - Jeremy S Davis
- Department of Biology, University of KentuckyLexingtonUnited States
| | - Leonie C Moyle
- Department of Biology, Indiana UniversityBloomingtonUnited States
| | - Giulia Manoli
- Neurobiology and Genetics, Theodor Boveri Institute, Biocentre, University of WürzburgWürzburgGermany
| | - Enrico Bertolini
- Neurobiology and Genetics, Theodor Boveri Institute, Biocentre, University of WürzburgWürzburgGermany
| | - Vladimír Košťál
- Institute of Entomology, Biology Centre, Academy of Sciences of the Czech RepublicPragueCzech Republic
| | - R Scott Hawley
- Department of Molecular and Integrative Physiology, University of Kansas Medical Center, Stowers Institute for Medical ResearchKansas CityUnited States
| | - Aya Takahashi
- Department of Biological Sciences, Tokyo Metropolitan UniversityHachiojiJapan
| | - Corbin D Jones
- Biology Department, University of North CarolinaChapel HillUnited States
| | - Donald K Price
- School of Life Science, University of NevadaLas VegasUnited States
| | - Noah Whiteman
- Department of Integrative Biology, University of California, BerkeleyBerkeleyUnited States
| | - Artyom Kopp
- Department of Evolution and Ecology, University of California DavisDavisUnited States
| | - Daniel R Matute
- Biology Department, University of North CarolinaChapel HillUnited States
| | - Dmitri A Petrov
- Department of Biology, Stanford UniversityStanfordUnited States
| |
Collapse
|
6
|
Timme CR, Alcoser SY, Breen D, Carter J, Chang TC, Chen A, Chen L, Cooley K, Das B, Delaney E, Eugeni MA, Gottholm-Ahalt MM, Grinnage-Polley T, Hull J, Karlovich C, Klarmann K, Jiwani S, Mallow C, McGlynn C, Mills J, Morris M, Mullendore M, Newton D, Shearer T, Stottlemyer J, Uzelac S, Walsh T, Williams PM, Evrard YA, Hollingshead MG, Doroshow JH. Abstract 3012: Patient-derived models of rare cancers in the National Cancer Institute's patient-derived models repository. Cancer Res 2021. [DOI: 10.1158/1538-7445.am2021-3012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
There is an unmet need for preclinical models of rare cancers and rare disease sub-types. The National Cancer Institute's Patient-Derived Models Repository (NCI PDMR; https://pdmr.cancer.gov) is developing quality-controlled, early-passage, clinically-annotated patient-derived tumor xenografts (PDXs), in vitro tumor cell cultures (PDCs), cancer associated fibroblasts (CAFs), and patient-derived organoids (PDOrg) and has focused on addressing unmet needs in the preclinical model space including developing models from adult and pediatric patients with rare cancers. To date, NCI has created and molecularly characterized over 150 preclinical models of rare cancer including indications such as Hurthle cell carcinoma, osteosarcomas, Merkel cell carcinomas, salivary gland cancers, synovial sarcomas, and carcinosarcomas. Rare cancer models developed to date will be reviewed and their histopathologic and molecular characteristics compared to that reported in the clinical setting. A pipeline to identify fusion proteins in these rare cancers such as the Ewing sarcoma EWSR1-FLI1 fusion and NAB2-STAT6 fusions in solitary fibrous tumors (SFT) has been implemented. Four malignant peripheral nerve sheath tumors (MPNST) PDX models are available for researches; these models were developed from patients diagnosed between the ages of 37-68. At the time of model development, two patients were treatment naïve and two had prior radiotherapy. Two of the MPNST PDX models have NF1 oncogenic mutations, three have deep deletions in CDKN2A/B, and three have a mutation in either EED or SUZ12 consistent with the reported molecular characteristics of patients with MPNST. Also of clinical relevance, of two mesothelioma models available, one carries an NF2 driver mutation and the other BAP1 and LATS2 and a PDX model for Hurthle cell carcinoma has wide-spread loss of heterozygosity (LOH 80%). Models for other rare cancers are in development, including four cholangiocarcinoma PDXs with histopathologic confirmation that are currently being expanded for molecular characterization and distribution. Funded by NCI Contract No. HHSN261200800001E
Citation Format: Cindy R. Timme, Sergio Y. Alcoser, Devynn Breen, John Carter, Ting-Chia Chang, Alice Chen, Li Chen, Kristen Cooley, Biswajit Das, Emily Delaney, Michelle A. Eugeni, Michelle M. Gottholm-Ahalt, Tara Grinnage-Polley, Jenna Hull, Chris Karlovich, Kimberly Klarmann, Shahanawaz Jiwani, Candace Mallow, Chelsea McGlynn, Justine Mills, Malorie Morris, Michael Mullendore, Dianne Newton, Tia Shearer, Jesse Stottlemyer, Shannon Uzelac, Thomas Walsh, P. Mickey Williams, Yvonne A. Evrard, Melinda G. Hollingshead, James H. Doroshow. Patient-derived models of rare cancers in the National Cancer Institute's patient-derived models repository [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 3012.
Collapse
Affiliation(s)
- Cindy R. Timme
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | | | - Devynn Breen
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - John Carter
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Ting-Chia Chang
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Alice Chen
- 3National Cancer Institute, Frederick, MD
| | - Li Chen
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Kristen Cooley
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Biswajit Das
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Emily Delaney
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | | | | | | | - Jenna Hull
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Chris Karlovich
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | | | | | - Candace Mallow
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Chelsea McGlynn
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Justine Mills
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Malorie Morris
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | | | - Dianne Newton
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Tia Shearer
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | | | - Shannon Uzelac
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Thomas Walsh
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | | | - Yvonne A. Evrard
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | | | | |
Collapse
|
7
|
Evrard YA, Alcoser SY, Borgel S, Breen D, Carter J, Chase T, Chen A, Chen L, Cooley K, Das B, Delaney E, Dutko L, Ecker S, Forbes T, Georgius K, Gottholm-Ahalt MM, Grinnage-Pulley T, Hoffman S, Karlovich C, Klarmann K, Jiwani S, Mills J, Morris M, Mullendore M, Newton D, Rivera G, Stotler H, Stottlemyer J, Styers S, Timme CR, Trail D, Uzelac S, Vilimas T, Walsh T, Walters N, Williams PM, Hollingshead MG, Doroshow JH. Abstract 3010: Single agent response comparisons in a large-scale, preclinical trial of rare cancer PDXs by the National Cancer Institute's patient-derived models repository. Cancer Res 2021. [DOI: 10.1158/1538-7445.am2021-3010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
The National Cancer Institute's Patient-Derived Models Repository (NCI PDMR; https://pdmr.cancer.gov) is performing a large-scale preclinical study with 39 patient-derived xenograft (PDX) models of rare cancers (including mesothelioma, MPNST, osteosarcoma, Merkel cell carcinoma) treated with 56 novel therapeutic combinations (targeted and cytotoxic agents) in an exploratory, n-of-4 arm, study design. Drug combinations with additive activity may undergo clinical evaluation in patients with rare cancers. PDX tumors are treated with a set of 8 combinations plus relevant vehicle controls while in parallel enough PDXs are serially passaged for the next passage and drug set. Every serial passage undergoes several quality control assessments that serve as go/no-go criteria. Combinations that show promising responses (e.g., regression or durable tumor growth inhibition) are repeated along with the single agent arms to determine if the response is driven by the combination or only one of the agents. We are currently at the half-way point in the overall study and here report interim results for the early combination agents that have single agent data for comparison. In a combination of a VEGFi and EGFRi, 6/37 models achieved a partial regression (30% shrinkage for more than one consecutive time point) and 17/37 had tumor growth inhibition while drug was on board. Single agent studies have been completed for 17/37 models with this combination and 7/9 responses were due to at least an additive effect of the combination. In contrast, while an HDACi + nucleoside analog combination had 16/36 responsive models, response in most of the single agent studies was due to only one of the agents. As part of this study, 3 models have been identified that have responded to at least 50% of the combinations tested possibly indicating a hypersensitive phenotype: two Merkel cell carcinomas (n=28 and 32) and one Neuroendocrine carcinoma (n=27). There is no immediate link between mechanism of action of the agents in the combinations, and the two Merkel cell carcinoma responses only had a moderate overlap. Finally, two Rhabdomyosarcoma models in the study have been the least responsive models to date. Funded by NCI Contract No. HHSN261200800001E
Citation Format: Yvonne A. Evrard, Sergio Y. Alcoser, Suzanne Borgel, Devynn Breen, John Carter, Tiffanie Chase, Alice Chen, Li Chen, Kristen Cooley, Biswajit Das, Emily Delaney, Lyndsay Dutko, Shannon Ecker, Thomas Forbes, Kyle Georgius, Michelle M. Gottholm-Ahalt, Tara Grinnage-Pulley, Sierra Hoffman, Chris Karlovich, Kimberly Klarmann, Shahanawaz Jiwani, Justine Mills, Malorie Morris, Michael Mullendore, Dianne Newton, Gloryvee Rivera, Howard Stotler, Jesse Stottlemyer, Savanna Styers, Cindy R. Timme, Debbie Trail, Shannon Uzelac, Tomas Vilimas, Thomas Walsh, Nikki Walters, P. Mickey Williams, Melinda G. Hollingshead, James H. Doroshow. Single agent response comparisons in a large-scale, preclinical trial of rare cancer PDXs by the National Cancer Institute's patient-derived models repository [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 3010.
Collapse
Affiliation(s)
- Yvonne A. Evrard
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | | | - Suzanne Borgel
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Devynn Breen
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - John Carter
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Tiffanie Chase
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Alice Chen
- 3National Cancer Institute, Frederick, MD
| | - Li Chen
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Kristen Cooley
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Biswajit Das
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Emily Delaney
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Lyndsay Dutko
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Shannon Ecker
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Thomas Forbes
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Kyle Georgius
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | | | | | - Sierra Hoffman
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Chris Karlovich
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | | | | | - Justine Mills
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Malorie Morris
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | | | - Dianne Newton
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Gloryvee Rivera
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Howard Stotler
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | | | - Savanna Styers
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Cindy R. Timme
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Debbie Trail
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Shannon Uzelac
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Tomas Vilimas
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Thomas Walsh
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Nikki Walters
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | | | | | | |
Collapse
|
8
|
Dutko L, Rivera G, Cantu E, Rahulkannan V, Benauer K, Chase T, Delaney E, Stottlemyer J, McGlynn C, Stotler H, Carter J, Borgel S, Ahalt MMG, Eugeni M, Hollingshead M, Evrard Y, Karlovich C, Das B, Williams M, Doroshow JH, Jiwani S. Abstract 3015: Applications of immunohistochemistry in characterization of patient derived xenograft models. Cancer Res 2021. [DOI: 10.1158/1538-7445.am2021-3015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Well characterized patient derived xenograft models (PDX) are becoming the preferred pre-clinical tool in translational cancer research for biologic understanding of the disease, development of new treatments, and identifying potential therapy predictive and resistant biomarkers. Characterization of PDX models using a multi-omic approach is most desirable, however such efforts can be expensive and technically demanding. Immunohistochemistry (IHC) has become an indispensable ancillary tool in the accurate classification of tumor types, determination of cell of origin, identification of biologic properties like growth and metastatic potential, and evaluation for the presence/absence of therapeutic or prognostic biomarkers.
Methods: 43 IHC assays were validated on the Leica Bond RX automated staining platform to identify common inconsistencies in PDX development including markers for classifying carcinomas, lymphomas, sarcomas, murine tumors, and theragnostic biomarkers. Rabbit antibodies are used rather than mouse antibodies to prevent non-specific staining of murine tissue.
Results: 1. IHC evaluation of models within NCI's Patient Derived Models Repository (pdmr.cancer.gov) led to re-classification or sub-classification of 12 tumor models in accordance with WHO guidelines. 2. IHC evaluation of theragnostic markers in 8 breast cancer PDX models showed concordant results throughout passaging, suggesting stability of these biomarkers in our models. 3. We observe malignant transformation of murine or transplanted benign human tissue at a rate of 2.5%. On IHC analysis, 52% were human lymphomas, 20% were murine lymphomas, and 28% were other murine tumors.
Conclusions: IHC is a rapid, cost-effective tool that can be used for accurate tumor classification, identifying subclonal outgrowth and tumor evolution, assessing stability of biomarkers and identifying malignant transformation of benign tissue. Funded by NCI Contract No. HHSN261200800001E
ANTIBODYCLONEVENDORANTIBODYCLONEVENDORAndrogen Receptor[EPR1535(2)]abcamGATA3[EPR16651]abcamB-Catenin[E247]abcamGCDFP-15[EPR1582Y]abcamCD19polyclonalabcamGFAPpolyclonalDAKO/AgilentCD3polyclonalabcamHER2 ErbB2[SP3]abcamCD20[SP32]abcamKi-67[D2H10]Cell SignalingCD34[EP373Y]abcamKu80[EPR3468]abcamCD45polyclonalabcamMGMTMT3.1MilliporeCD56 (NCAM1)[EPR2566]abcamMitochondria Marker (Biotin)MTC02abcamCD68[EPR20545]abcamMyogenin[EPR4789]abcamCDX2[EPR2764Y]abcamNAPSIN A[EPR6252]abcamChromogranin A[SP12]abcamp63polyclonalGeneTexCK7 (purified)[EPR1619Y]abcamPD-1[EPR4877(2)]abcamCK19[EPR1580Y]abcamPD-L1 (CD274)RBT-PDL1LifeSpan BiosciencesCK20[EPR1622Y]abcamProgesterone Receptor[SP2]abcamCytokeratin wide spectrumpolyclonalabcamProstate Specific Antigen (PSA)[EP1588Y]abcamDesmin[Y66]abcamS100[EPR19013]abcamEBV LMP1[D24-G]abcamSmooth Muscle Actin (SMA)polyclonalabcamERG[EPR3864]abcamSynaptophysin[SP11]abcamEstrogen Receptor[SP1]abcamTTF1[SP141]abcamFOXP1monoclonalLifeSpan BiosciencesVimentin[EPR3776]abcamFOXP3(5H10L18)Invitrogen
Citation Format: Lindsay Dutko, Gloryvee Rivera, Erin Cantu, Vishnuprabha Rahulkannan, Kelly Benauer, Tiffanie Chase, Emily Delaney, Jesse Stottlemyer, Chelsea McGlynn, Howard Stotler, John Carter, Suzanne Borgel, Michelle M. Gottholm Ahalt, Michelle Eugeni, Melinda Hollingshead, Yvonne Evrard, Chris Karlovich, Biswajit Das, Mickey Williams, James H. Doroshow, Shahanawaz Jiwani. Applications of immunohistochemistry in characterization of patient derived xenograft models [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 3015.
Collapse
Affiliation(s)
| | | | - Erin Cantu
- 1Leidos Biomedical Research, Inc., Frederick, MD
| | | | | | | | | | | | | | | | - John Carter
- 1Leidos Biomedical Research, Inc., Frederick, MD
| | | | | | | | | | | | | | - Biswajit Das
- 1Leidos Biomedical Research, Inc., Frederick, MD
| | | | | | | |
Collapse
|
9
|
Evrard YA, Das B, Alcoser SY, Borgel S, Breen D, Carter J, Chase T, Chen A, Chen L, Cooley K, Delaney E, Divelbiss R, Dutko L, Forbes T, Georgius K, Gottholm-Ahalt M, Grinnage-Pulley T, Hoffman S, Karlovich C, Jiwani S, Mills J, Morris M, Mullendore M, Newton D, Patidar R, Rivera G, Stotler H, Stottlemyer J, Styers S, Trail D, Uzelac S, Vilimas T, Walke A, Walsh T, Walters N, Wang P, Williams PM, Hollingshead M, Doroshow JH. Abstract 5056: Quality control efforts in a large-scale, preclinical trial of rare cancer PDXs by the National Cancer Institute's patient-derived models repository (NCI PDMR). Cancer Res 2020. [DOI: 10.1158/1538-7445.am2020-5056] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
The National Cancer Institute's Patient-Derived Models Repository (NCI PDMR; https://pdmr.cancer.gov) is performing a large-scale multi-year preclinical study with 39 PDX models of rare cancers (mesothelioma, MPNST, osteosarcoma, Merkel cell carcinoma, etc) treated with 56 novel therapeutic combinations in an exploratory, n-of-4 arm, study design. Combinations that show promising responses (e.g., regression or durable inhibition of tumor growth) will be repeated along with the single agent arms to determine if the response is driven by the combination or only one of the agents. In order to do this in a timely fashion, relatively speaking, the PDX tumors are serially passaged and each passage is treated with a set of 8 combinations plus relevant vehicle control(s) while in parallel enough PDXs are retained to be expanded for the next passage and drug set. Every serial passage undergoes several quality control assessments that serve as go/no-go criteria including pathology assessment, human:mouse DNA content assessment, and low pass whole genome sequencing to determine the average fraction of genome changed compared to the original donor material. If there is a QC failure, the PDX model is restarted from early passage cryo-material (passage 1-2). An additional quality control effort is to bookend the combination studies with the first set of agents to see if tumor response is similar across passages. To date, most of the models have demonstrated a high degree of stability, though a couple of models have moved toward murine content and have been restarted from early passage material so all drug combinations can be tested. DNA and RNA are retained from all passages so a full NGS evaluation can be performed at a later date. This effort has been ongoing for over a year and the first bookend studies are beginning to be tested to determine if response at first and last passage of the study are consistent with each other, given the constraints of the inherent heterogeneity of the models themselves. Single agent studies of drug combinations that demonstrated a response in 30%-50% of the models tested are also underway to determine which combinations have a more than additive effect compared to the single agents. Promising combinations will be moved forward to early phase clinical trials for these rare cancers.
Funded by NCI Contract No. HHSN261200800001E
Citation Format: Yvonne A. Evrard, Biswajit Das, Sergio Y. Alcoser, Suzanne Borgel, Devynn Breen, John Carter, Tiffanie Chase, Alice Chen, Lily Chen, Kristen Cooley, Emily Delaney, Raymond Divelbiss, Lyndsay Dutko, Thomas Forbes, Kyle Georgius, Michelle Gottholm-Ahalt, Tara Grinnage-Pulley, Sierra Hoffman, Chris Karlovich, Shahanawaz Jiwani, Justine Mills, Malorie Morris, Michael Mullendore, Dianne Newton, Rajesh Patidar, Gloryvee Rivera, Howard Stotler, Jesse Stottlemyer, Savanna Styers, Debbie Trail, Shannon Uzelac, Thomas Vilimas, Abigail Walke, Thomas Walsh, Nicole Walters, Peng Wang, P. Mickey Williams, Melinda Hollingshead, James H. Doroshow. Quality control efforts in a large-scale, preclinical trial of rare cancer PDXs by the National Cancer Institute's patient-derived models repository (NCI PDMR) [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 5056.
Collapse
Affiliation(s)
- Yvonne A. Evrard
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Biswajit Das
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | | | - Suzanne Borgel
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Devynn Breen
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - John Carter
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Tiffanie Chase
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Alice Chen
- 2National Cancer Institute, Frederick, MD
| | - Lily Chen
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Kristen Cooley
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Emily Delaney
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | | | - Lyndsay Dutko
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Thomas Forbes
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Kyle Georgius
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | | | | | - Sierra Hoffman
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Chris Karlovich
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | | | - Justine Mills
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Malorie Morris
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | | | - Dianne Newton
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Rajesh Patidar
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Gloryvee Rivera
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Howard Stotler
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | | | - Savanna Styers
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Debbie Trail
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Shannon Uzelac
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Thomas Vilimas
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Abigail Walke
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Thomas Walsh
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Nicole Walters
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Peng Wang
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | | | | | | |
Collapse
|
10
|
Abstract
BACKGROUND/OBJECTIVES Social media use has been suggested to worsen psychiatric health among adolescents, especially those with visible skin lesions including acne. However, little is known about social media's impact on acne treatment. The purpose of the study sought to characterize the influence of social media use on acne treatment. METHODS We conducted a cross-sectional survey of West Virginia University ambulatory patients whose chief complaint was acne was conducted. The survey collected sociodemographics and queried whether individuals accessed social media for acne treatment advice or not, whether changes to acne care were made based on social media, and whether these changes aligned with the American Academy of Dermatology (AAD) clinical guidelines for acne management. RESULTS Of 130 respondents, 45% consulted social media for acne treatment advice (54% of women vs 31% of men). 41% of adolescents and 51% of adults consulted social media. The most used platforms were YouTube and Instagram (58% each). Social media users often tried an OTC treatment (81%) or dietary modification (40%). However, only 31% of participants consulting social media made changes fully aligned with AAD clinical guidelines. CONCLUSIONS Social media-influenced acne treatment advice is prevalent, especially among women, adolescents, and young adults. This treatment advice frequently does not align with AAD guidelines, with notably 40% of respondents choosing dietary modification for acne management. These results suggest that dermatologists should inquire about social media acne treatment advice and directly address misinformation.
Collapse
Affiliation(s)
- Ahmed Yousaf
- Department of Dermatology, West Virginia University, Morgantown, WV, USA
| | - Rachael Hagen
- Department of Dermatology, West Virginia University, Morgantown, WV, USA.,West Virginia School of Osteopathic Medicine, Lewisburg, WV, USA
| | - Emily Delaney
- Department of Dermatology, West Virginia University, Morgantown, WV, USA
| | - Stephen Davis
- Department of Health Policy, Management & Leadership, West Virginia University, Morgantown, WV, USA.,Department of Emergency Medicine, West Virginia University, Morgantown, WV, USA
| | - Zachary Zinn
- Department of Dermatology, West Virginia University, Morgantown, WV, USA
| |
Collapse
|
11
|
Evrard YA, Newton D, Das B, Alcoser SY, Arthur K, Baldwin M, Bonomi C, Borgel S, Carter J, Chase T, Chen A, Chen L, Craig NE, Datta V, Delaney E, Divelbiss R, Dougherty K, Forbes T, Georgius K, Geraghty J, Gibson M, Gottholm-Ahalt MM, Grinnage-Pulley T, Hedger K, Hoffman S, Karlovich C, Lassoued W, Jiwani S, Mallow C, McGlynn C, Morris M, Moyer J, Mullendore M, Murphy M, Patidar R, Plater K, Radzyminski M, Scott N, Stockwin LH, Stotler H, Stottlemyer J, Styers S, Trail D, Vilimas T, Wade A, Walke A, Walsh T, Williams PM, Hollingshead MG, Doroshow JH. Abstract 4524: Comparison of PDX, PDC, and PDOrg models from the National Cancer Institute’s Patient-Derived Models Repository (PDMR). Cancer Res 2019. [DOI: 10.1158/1538-7445.am2019-4524] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
The National Cancer Institute (NCI) has developed a Patient-Derived Models Repository (PDMR) comprised of quality-controlled, early-passage, clinically-annotated patient-derived tumor xenografts (PDXs), in vitro tumor cell cultures (PDCs), cancer associated fibroblasts (CAFs), and patient-derived organoids (PDOrg). NCI has focused on generating models to complement existing PDX collections and address unmet needs in the preclinical model space. These models are offered to the extramural community for research use (https://pdmr.cancer.gov), along with clinical annotation and molecular information (whole exome sequence, gene expression using RNASeq), via a publicly accessible database. Currently, over 200 PDX models, 50 PDC models, and 100 CAF models are available for distribution to the US research community. Approximately 50 PDOrg models will be released in early 2019. As part of its rare cancer initiative, the NCI is also targeting the collection of infrequently-observed tumor histologies to advance both biological investigations and drug development efforts for under-studied malignancies. Comparison of matched models, models where more than one model type are available (e.g., PDX and PDC), demonstrate a high degree of concordance across the model types. Genetic stability across the models is assessed using multiple criteria including genetic assessment of CNVs and presence of driver mutations. Optimal CNV assessment uses whole exome sequence data corrected for cellularity in the patient specimen using germline reads and corrected for cellularity in the PDX specimens by subtraction of the mouse reads. Histomorphologic comparison of PDXs and cell line xenografts (CLX) generated from in vitro PDCs and PDOrgs also overall show a high degree of concordance, though loss of features and dedifferentiation can be observed in some models. Overall these models demonstrate a high degree of conservation at the genetic and pathologic level when compared to the patient tumor. These models can provide researchers the ability to perform high- or mid-throughput screening in 2D or 3D culture followed by targeted selection of PDX models for in vivo studies. Funded by NCI Contract No. HHSN261200800001E
Citation Format: Yvonne A. Evrard, Dianne Newton, Biswajit Das, Sergio Y. Alcoser, Kaitlyn Arthur, Mariah Baldwin, Carrie Bonomi, Suzanne Borgel, John Carter, Tiffany Chase, Alice Chen, Lily Chen, Nikki E. Craig, Vivekananda Datta, Emily Delaney, Raymond Divelbiss, Kelly Dougherty, Thomas Forbes, Kyle Georgius, Joe Geraghty, Marion Gibson, Michelle M. Gottholm-Ahalt, Tara Grinnage-Pulley, Kelly Hedger, Sierra Hoffman, Chris Karlovich, Wiem Lassoued, Shahanawaz Jiwani, Candace Mallow, Chelsea McGlynn, Mallorie Morris, Jenna Moyer, Mike Mullendore, Matt Murphy, Rajesh Patidar, Kevin Plater, Marianne Radzyminski, Nicki Scott, Luke H. Stockwin, Howard Stotler, Jesse Stottlemyer, Savanna Styers, Debbie Trail, Tomas Vilimas, Anna Wade, Abigail Walke, Thomas Walsh, P. Mickey Williams, Melinda G. Hollingshead, James H. Doroshow. Comparison of PDX, PDC, and PDOrg models from the National Cancer Institute’s Patient-Derived Models Repository (PDMR) [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 4524.
Collapse
Affiliation(s)
- Yvonne A. Evrard
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Dianne Newton
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Biswajit Das
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | | | - Kaitlyn Arthur
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Mariah Baldwin
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Carrie Bonomi
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Suzanne Borgel
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - John Carter
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Tiffany Chase
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Alice Chen
- 2National Cancer Institute, Frederick, MD
| | - Lily Chen
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Nikki E. Craig
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | | | - Emily Delaney
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | | | - Kelly Dougherty
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Thomas Forbes
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Kyle Georgius
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Joe Geraghty
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Marion Gibson
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | | | | | - Kelly Hedger
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Sierra Hoffman
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Chris Karlovich
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Wiem Lassoued
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | | | - Candace Mallow
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Chelsea McGlynn
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Mallorie Morris
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Jenna Moyer
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Mike Mullendore
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Matt Murphy
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Rajesh Patidar
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Kevin Plater
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | | | - Nicki Scott
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Luke H. Stockwin
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Howard Stotler
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | | | - Savanna Styers
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Debbie Trail
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Tomas Vilimas
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Anna Wade
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Abigail Walke
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Thomas Walsh
- 1Frederick National Laboratory for Cancer Research, Frederick, MD
| | | | | | | |
Collapse
|
12
|
Moschino V, Delaney E, Da Ros L. Assessing the significance of Ruditapes philippinarum as a sentinel for sediment pollution: bioaccumulation and biomarker responses. Environ Pollut 2012; 171:52-60. [PMID: 22871644 DOI: 10.1016/j.envpol.2012.07.024] [Citation(s) in RCA: 48] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/15/2012] [Revised: 06/27/2012] [Accepted: 07/06/2012] [Indexed: 06/01/2023]
Abstract
The present study assessed whether the bivalve Ruditapes philippinarum may be appropriately deployed as a bioindicator in monitoring transitional environments, in terms of bioaccumulation potential and biomarker responses. The concentrations of trace metals, PAHs and PCBs were determined in sediments and clam tissue, and biomarkers were estimated at various levels of biological complexity (i.e. metallothioneins, lipofuscins, survival-in-air and reburrowing behaviour). Sediments and clams were collected biannually in 2004 and 2005 at eight sites within Venice lagoon, which were influenced differently by natural and anthropogenic impacts. Results highlighted that the broad variations of pollutant concentrations in sediments were not consistent either with the body residuals or with the biomarker responses. Consequently, on the basis of the observed weak responsiveness and sensitivity to anthropogenic stressors we suggest a more cautious use for R. philippinarum as sentinel organism, at least in estuarine sediments in the north Adriatic transitional areas.
Collapse
Affiliation(s)
- V Moschino
- Institute of Marine Sciences (ISMAR-CNR), Castello 1364/A, 30122 Venezia, Italy.
| | | | | |
Collapse
|
13
|
Iversen L, Delaney E, Hannaford P, Black C. IS THE MENOPAUSE STILL A WORKLOAD ISSUE IN UK GENERAL PRACTICE? A RETROSPECTIVE ANALYSIS OF THE GENERAL PRACTICE RESEARCH DATABASE. Maturitas 2009. [DOI: 10.1016/s0378-5122(09)70268-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
14
|
Gray NF, Delaney E. Comparison of benthic macroinvertebrate indices for the assessment of the impact of acid mine drainage on an Irish river below an abandoned Cu-S mine. Environ Pollut 2008; 155:31-40. [PMID: 18093710 DOI: 10.1016/j.envpol.2007.11.002] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/04/2007] [Revised: 09/21/2007] [Accepted: 11/02/2007] [Indexed: 05/25/2023]
Abstract
A range of macroinvertebrate indices were compared to assess the most appropriate metric for the assessment of acid mine drainage (AMD) in a low alkalinity, highly erosional river in south-east Ireland. Differences were found in the ability of indices to discriminate AMD impact with the Brillouin, BMWP score, Margalef and Shannon Indices the most precise. Taxon richness was also strongly correlated with AMD indicator parameters (e.g. pH alkalinity, sulphate, Zn and Fe) at impacted sites being an equally reliable metric. The response of the community structure to AMD in this river does not fulfil the optimum criteria for either diversity or biological indices, which may explain the variation in the success of different indices seen in this and other studies. The development of indices that model the expected community response to AMD more accurately or are based on the response of indicator species to AMD pollutants are required.
Collapse
Affiliation(s)
- N F Gray
- Centre for the Environment, Trinity College, Dublin 2, Ireland.
| | | |
Collapse
|
15
|
McNally OM, Delaney E, Petty RD, Cruickshank ME, Hutcheon AW, Parkin DE. Is optimal first-line chemotherapy deliverable in all newly diagnosed ovarian cancers? A population-based study. Br J Cancer 2003; 89:966-7. [PMID: 12966409 PMCID: PMC2376968 DOI: 10.1038/sj.bjc.6601071] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Abstract
NICE guidance recommends the use of paclitaxel and a platinum therapy for all cases of ovarian cancer. We report our experience of treating 133 patients with ovarian cancer over a 3-year period. Where indicated, 91% received chemotherapy. A taxane/platinum combination was found to be appropriate in 63% of patients only.
Collapse
Affiliation(s)
- O M McNally
- Department of Gynaecology/Oncology, Ward 43, Aberdeen Royal Infirmary, Foresterhill, Aberdeen AB15 2ZN, Scotland.
| | | | | | | | | | | |
Collapse
|
16
|
Pachner AR, Delaney E, Zhang WF, O'Neill T, Major E, Frey AB, Davidson E. Protection from Lyme neuroborreliosis in nonhuman primates with a multiantigenic vaccine. Clin Immunol 1999; 91:310-3. [PMID: 10370376 DOI: 10.1006/clim.1999.4703] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
In an effort to develop an effective and safe vaccine for lyme disease, rhesus macaques were injected with a multiantigenic preparation of Borrelia burgdorferi, strain N40. One month later animals were boosted before intradermal challenge with infectious B. burgdorferi. Challenges were performed at 1 and again at 5 months after the booster vaccination. Vaccinated and control nonvaccinated animals were monitored for development of systemic infection by measurement of serum anti-spirochetal antibodies by ELISA and Western blotting, and neurological involvement was monitored by testing of cerebrospinal fluid (CSF) and PCR analysis of central nervous system (CNS) tissue obtained at necropsy. Two control nonhuman primates (NHPs), given saline injections instead of vaccine and then challenged with B. burgdorferi, developed CSF pleocytosis, PCR positivity of the brain, and high levels of specific anti-B. burgdorferi antibody in the serum and CSF. Necropsy studies revealed widespread invasion of the CNS of one of these animals by the spirochete. In contrast, none of the four vaccinated animals developed evidence of invasion of the CNS after either of two challenge inoculations with infectious B. burgdorferi. In addition to resisting infection, no vaccinated animal demonstrated any untoward consequence of vaccination. These data demonstrate that a multiantigenic vaccine is effective in preventing systemic infection and lyme neuroboreliosis in NHPs and suggest that a successful vaccine could be developed in humans which would prevent lyme disease.
Collapse
Affiliation(s)
- A R Pachner
- Georgetown University School of Medicine, Washington, DC, USA
| | | | | | | | | | | | | |
Collapse
|
17
|
Pachner AR, Amemiya K, Delaney E, O'Neill T, Hughes CA, Zhang WF. Interleukin-6 is expressed at high levels in the CNS in Lyme neuroborreliosis. Neurology 1997; 49:147-52. [PMID: 9222183 DOI: 10.1212/wnl.49.1.147] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023] Open
Abstract
In patients with Lyme neuroborreliosis, inflammation and symptoms of fatigue and malaise occur out of proportion to the relatively low number of spirochetes present. Previous studies have identified interleukin-6 (IL-6) as a candidate molecule for amplification of CNS inflammation in this disease. We pursued this possibility by measuring cytokine gene expression by reverse-transcriptase polymerase chain reaction (RT-PCR) in the brain of rhesus macaques actively infected with Borrelia burgdorferi. Samples of brain tissue were screened for IL-6 and interferon gamma using RT-PCR-ELISA, a technique that uses RT-PCR, subsequent hybridization of the PCR product with a biotinylated probe, and capture and ELISA readout of hybridization product. The number of copies in positive samples was then quantitated using qRT-PCR-ELISA, in which wild-type cytokine cDNA competes with recombinant competitor DNA in the PCR. Elevated levels of IL-6 cDNA and, to a lesser extent, interferon gamma were detected in three of three nonhuman primates with persistent infection with B burgdorferi, whereas the brains of three uninfected animals and undetectable levels of gene expression of these cytokines. These data support the hypothesis that cytokines such as IL-6 are important amplification molecules for CNS inflammation in Lyme neuroborreliosis.
Collapse
Affiliation(s)
- A R Pachner
- Department of Neurology, Georgetown University School of Medicine, Washington, DC 20007, USA
| | | | | | | | | | | |
Collapse
|
18
|
Abstract
Neurological involvement in Lyme disease is common, and is frequently difficult to diagnose and treat. Little is known about the fate of the causative spirochete Borrelia burgdorferi in the central nervous system (CNS). To determine the frequency of parenchymal infection and to determine localization of the organism, polymerase chain reaction/hybridization assays were performed in a newly described model of Lyme neuroborreliosis in nonhuman primates infected with B. burgdorferi. Polymerase chain reaction/hybridization of CNS tissues from 5 infected nonhuman primates was performed. Substantial amounts of B. burgdorferi DNA were detected in the CNS in all infected animals, with a predilection toward subtentorial structures. These data suggest that Lyme neuroborreliosis represents persistent infection with B. burgdorferi.
Collapse
Affiliation(s)
- A R Pachner
- Department of Neurology, Georgetown University School of Medicine, Washington, DC 20007, USA
| | | | | |
Collapse
|
19
|
Abstract
Lyme borreliosis is a newly recognized systemic infection with protean clinical manifestations. Because the localization of the causative spirochete (Borrelia burgdorferi) in infected tissues is unknown, we used electron microscopy to find spirochetes in the hearts of chronically infected mice. There were three predominant locations for the spirochete in the hearts. In mice infected for one month or less, the spirochetes were mostly in or around blood vessels. They were either in the lumen or in the perivascular space. Mice infected for more than one month had B. burgdorferi in cardiac myocytes as well, often with clear spaces around them. The third area in which spirochetes were common was collagen fibers; the borreliae were wrapped around fibers with their long axis parallel to the fibers. The number of spirochetes was relatively low, but there was no appreciable decrease in numbers of spirochetes with increasing time postinfection. Inflammatory infiltrates were primarily in the endocardium and pericardium, but spirochetes were generally not in or near areas of inflammation. These data are consistent with previously published information that have identified the heart as a site of chronic infection and inflammation in the mouse. The studies extend our understanding of the behavior of the spirochete in vivo by identifying common locations of B. burgdorferi and by noting the disparity between infection and inflammation.
Collapse
Affiliation(s)
- A R Pachner
- National Institute of Public Health, Department of Electron Microscopy, Prague, Czech Republic
| | | | | | | |
Collapse
|
20
|
Pachner AR, Delaney E, O'Neill T, Major E. Inoculation of nonhuman primates with the N40 strain of Borrelia burgdorferi leads to a model of Lyme neuroborreliosis faithful to the human disease. Neurology 1995; 45:165-72. [PMID: 7824109 DOI: 10.1212/wnl.45.1.165] [Citation(s) in RCA: 67] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023] Open
Abstract
We injected rhesus macaques with a highly infective strain of Borrelia burgdorferi to assess whether experimentally inoculated nonhuman primates (NHPs) could serve as models of human Lyme neuroborreliosis (LNB). The animals developed biopsy-confirmed erythema migrans in the area of the inoculations. ELISA testing of sera revealed strong antibody reactivity to B burgdorferi antigens, and Western blotting showed that 16-, 22-, 31-, 34-, and 41-kd proteins of the spirochete were major antigens recognized by antibody. Culture and polymerase chain reaction (PCR) testing of serial CSF specimens revealed that chronic infection of the CNS occurred in all NHPs injected. CSF pleocytosis occurred concurrently with CNS infection. Brain MRI revealed intense meningeal inflammation in one NHP as manifested by gadolinium uptake by the dura at the base of the temporal lobes. All animals had measurable antibody in the CSF after invasion. These studies are the first to demonstrate that experimental LNB in NHPs is a reliable model faithful to the human disease, with spirochetal invasion of the subarachnoid space. This also is the first report of CSF samples positive by culture in experimental LNB. Inflammation in the CNS as manifested by CSF pleocytosis and MRI findings was also correlated with the presence of spirochetal DNA detected by PCR. These data support the hypothesis that the pathogenesis of LNB is associated with direct spirochetal invasion, and provide evidence that CNS involvement is more common than heretofore thought.
Collapse
Affiliation(s)
- A R Pachner
- Department of Neurology, Georgetown University Medical Center, Washington, DC
| | | | | | | |
Collapse
|
21
|
Pachner AR, Braswell ST, Delaney E, Amemiya K, Major E. A rabbit model of Lyme neuroborreliosis: characterization by PCR, serology, and sequencing of the OspA gene from the brain. Neurology 1994; 44:1938-43. [PMID: 7936251 DOI: 10.1212/wnl.44.10.1938] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023] Open
Abstract
To test whether rabbits can serve as a model for Lyme neuroborreliosis (LNB), we injected New Zealand white rabbits with Borrelia burgdorferi. We obtained samples of blood and CSF for culture, polymerase chain reaction/hybridization (PCR/H), serology, and Western blot. We then sacrificed the rabbits 2 to 3 months after infection and removed organs for culture and PCR/H analysis. The rabbits developed an antibody response, characterized by ELISA and Western blot analysis, consistent with a systemic infection. PCR/H and blood cultures were negative, but PCR/H analysis of CSF in one rabbit was positive. Positive PCR/H analysis of organs from the rabbits was consistent with widespread dissemination of the organism. The most consistently infected organ was the CNS. To determine whether antigenic variation occurred at the genetic level, we compared the sequences of the OspA gene of both the infecting strain and the brain PCR product. The differences between the two were minimal, indicating that variation in the OspA gene did not occur during in vivo infection in the rabbit. Thus, rabbits, after intradermal inoculation with B burgdorferi, develop a chronic systemic infection in which the CNS is a consistent target. These data indicate that rabbits may be an excellent model of LNB.
Collapse
Affiliation(s)
- A R Pachner
- Department of Neurology, Georgetown University Medical Center, Washington, DC
| | | | | | | | | |
Collapse
|
22
|
Abstract
The polymerase chain reaction is sensitive and specific in the detection of defined DNA sequences and holds promise for diagnosing the presence of fastidious microorganisms in human infectious diseases. We developed a methodology for nested polymerase chain reaction and hybridization analysis of the cerebrospinal fluid using primers from a genomic Borrelia burgdorferi sequence and applied it to the cerebrospinal fluid (CSF) of patients suspected of having Lyme neuroborreliosis and other diseases. Polymerase chain reaction and hybridization demonstrated extremely high sensitivity for spirochetal DNA, and was highly specific, with a false-positivity rate of less than 3%. However, the results were negative or indeterminate in 54% of CSF samples from patients with definite or probable disease, indicating an absence, or extremely low level, of spirochetes or spirochetal DNA in a significant percentage of patients with Lyme neuroborreliosis. Polymerase chain reaction and hybridization of the CSF can thus be considered a useful adjunct in diagnosis, but its negativity does not rule out Lyme neuroborreliosis.
Collapse
Affiliation(s)
- A R Pachner
- Department of Neurology, Georgetown University School of Medicine, Washington, DC
| | | |
Collapse
|
23
|
Pachner AR, Ricalton N, Delaney E. Comparison of polymerase chain reaction with culture and serology for diagnosis of murine experimental Lyme borreliosis. J Clin Microbiol 1993; 31:208-14. [PMID: 8432804 PMCID: PMC262737 DOI: 10.1128/jcm.31.2.208-214.1993] [Citation(s) in RCA: 29] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023] Open
Abstract
After the intradermal inoculation of mice with Borrelia burgdorferi, the antibody response, culture, and histology of blood and target organs were assessed and compared with results of a nested polymerase chain reaction (PCR) assay. Of 247 specimens of heart, brain, bladder, and blood, the tested concordance between the PCR and culture was 72%. In the 69 instances of discordance, the PCR was positive in 51 and the culture was positive in 18; thus, the PCR was concordant or more sensitive in 93% of the tested organs. In mice infected with 10 spirochetes, serology confirmed by Western blotting (immunoblotting) was more sensitive than either culture or PCR of brain, bladder, or heart specimens. The organs most commonly culture or PCR positive were the heart and bladder; the brain was infected in only 26% of the animals. DNA hybridization was helpful in confirming the PCR product as being specific and, in some cases, in demonstrating a positive product in the face of negative agarose gels. PCR was less sensitive than culture in detecting the presence of spirochetes in blood specimens, possibly because of the presence of blood inhibitors. We thus found a nested PCR assay, using primers from a genomic sequence, to be a valuable adjunct to serology and culture in the study of murine Lyme borreliosis. The assay confirmed that, after small numbers of spirochetes are injected intradermally, the heart and bladder, and less frequently the brain, are sites of persistence of the spirochetes.
Collapse
Affiliation(s)
- A R Pachner
- Department of Neurology, Georgetown University School of Medicine, Washington, D.C. 20007
| | | | | |
Collapse
|
24
|
Pachner AR, Delaney E, Ricalton NS. Murine Lyme borreliosis: route of inoculation determines immune response and infectivity. Reg Immunol 1992; 4:345-51. [PMID: 1297405] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
Outer surface protein A OspA is the major outer surface protein of B. burgdorferi, the causative agent of Lyme disease, and has been advocated as a vaccine candidate. It is recognized late or not at all in the course of human Lyme disease, but has been identified as a major antigenic epitope for the anti-spirochetal immune response in a number of experimental models of B. burgdorferi infection. We injected B.burgdorferi into mice and tested the appearance of immunoreactivity to OspA by Western blotting. Three routes of infection were studied; other variables investigated were inoculum size and isolate of spirochete and strain of mouse. OspA immunoreactivity, as determined by Western blotting, was readily elicited by injection of sonicates under almost any condition. Intraperitoneal or intravenous injection of infectious spirochetes, especially at infective inoculum sizes, or injection of the noninfectious B31 isolate by any route, resulted in OspA immunoreactivity. However, mice from the three strains tested infected intradermally did not develop significant OspA immunoreactivity, but instead developed strong responses to B.burgdorferi proteins of different molecular weights. These data suggest that during infection within the skin after intradermal inoculation, the OspA protein may be altered in some way to make it less immunogenic than when it is presented to the immune system under other circumstances.(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
Affiliation(s)
- A R Pachner
- Georgetown University School of Medicine, Department of Neurology, Washington, DC 20007
| | | | | |
Collapse
|
25
|
Lucey J, Gaffney R, Laher MS, Comerford J, Broe P, Ennis J, Bouchier-Hayes D, O’Malley K, Horgan JH, Lee RJE, MacLennan B, Beringer TRO, Ohman EM, Walsh T, Kelly J, O’Malley K, Nolan MT, FitzGerald MX, Delaney E, Carville P, Flanagan M, Turner M, Donovan D, Gillen P, FitzGerald GR, Watson RGP, O’Mahony C, O’Farrelly C, Thompson AJ, Brazil J, Martin EA, Feighery C, Hutchinson M, Mongey AB, Glynn D, Hutchinson M, Bresnihan B, Cox J, Gormley MJJ, Farrell R, Owens D, Tyrrell D, Tomkin GH. Royal academy of medicine in Ireland section of medicine. Ir J Med Sci 1985. [DOI: 10.1007/bf02937202] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|